کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2823911 | 1161451 | 2013 | 10 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis](/preview/png/2823911.png)
The immunomodulatory drugs for multiple sclerosis (MS) are associated with a variety of adverse drug reactions, including liver and cardiac injury, acute leukemia and progressive multifocal leukoencephalopathy. Minimizing or preventing the toxicity of MS drugs represents a major clinical objective. The science of pharmacogenomics is used to identify genetic variants associated with a high or low risk of experiencing a specific adverse drug reaction or therapeutic response. Combined with clinical and demographic factors, pharmacogenomics holds promise to better optimize a drugs’ risk/benefit profile. The application of pharmacogenomics for MS therapies is currently focused on finding markers of drug response.This review highlights the potential for pharmacogenomics to assist in predicting and/or preventing some of the more severe adverse reactions associated with MS therapies. We reviewed the literature surrounding seven serious adverse drug reactions associated with MS therapies, to serve as a springboard for future research: interferon-beta associated liver injury; lipoatrophy related to glatiramer acetate; progressive multifocal leukoencephalopathy associated with natalizumab, mitoxantrone associated cardiotoxicity and leukemia; and viral infections and cardiac effects associated with fingolimod. Predictive genetic testing for adverse drug reactions in the MS clinic could lead to a better risk profiling of patients before an MS therapy is initiated.
► MS immunomodulatory drugs are associated with a variety of adverse reactions.
► Pharmacogenomics and clinical factors can optimize a drugs’ benefit/risk profile.
► The application of pharmacogenomics to MS is currently focused on drug response.
► We review target adverse drug reactions in MS for future research purposes.
Journal: Multiple Sclerosis and Related Disorders - Volume 2, Issue 3, July 2013, Pages 183–192